Opiant Pharmaceuticals, Inc.

Infectious disease provided the backdrop for both of the US FDA’s novel approvals last week, one an antiviral and one an antibiotic. The antiviral is already familiar to patients and prescribers. Pfi

The US Federal Trade Commission has signaled that it would look more closely at biopharma acquisitions and might consider other factors than product overlap in determining their potential anticompetit

After abuse-deterrent opioid formulations reached a dead-end, the US Food and Drug Administration again is seeing growth in applications for new products that address the opioid crisis. In addition to

US Federal Trade Commissioner Christine Wilson’s plan to resign, which she announced in a 14 February Wall Street Journal commentary, will leave the agency with three Democratic commissioners and no v